| 标题 |
Giant-cell arteritis: Is glucocorticoid-sparing treatment still relevant? a retrospective study
巨细胞动脉炎：保留糖皮质激素的治疗仍然相关吗？回顾性研究
|
| 网址 |
求助人暂未提供
|
| DOI |
暂未提供，该求助的时间将会延长，查看原因？
|
| 其它 | 摘要：Background/Purpose: Giant-cell arteritis (GCA) is the most common primary large-vessel vasculitis affecting patients over 50 yr. Despite frequent and severe adverse events (AEs), glucocorticoids (GCs) are the reference treatment.1 In 2003, Proven et al reported GC-related AEs) in 86% of their patients.2 Efficacy of immunosuppressants, specifically methotrexate, is modest. Although tocilizumab is emerging as an alternative agent, the long-term benefit of IL6 blockade is unknown. Moreover, application of the most recent recommendations on GC-induced osteoporosis or vaccinations might change the GC-associated risks and, thus, the risk/benefit balance needs to be updated. We evaluated the GC-induced frequencies of AEs in a French cohort of GCA patients. |
| 求助人 | |
| 下载 | 暂无链接，等待应助者上传 |
cocolu
毛豆
SYLH
pluto
吡咯爱成环
Singularity
ceeray23
lyf471
芝麻糊
无名老大
火星上的菲鹰
Yifan2024
子车茗
iNk
方羽
cctv18
kento
tuanheqi
TN
丰知然
皖公网安备34019202002308
